News

Rouen, France, May 21, 2019 – Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, announces today that Pr Haude, Dr Lorgat and Pr Nef have joined its medical advisory board. All are global experts and recognized leaders in interventional cardiology.

The board plays a key role in defining the clinical strategy of the company. Their clinical work will contribute to the worldwide growth of robotics in interventional cardiology.

Philippe Bencteux, president…

Rouen, France, February 26, 2019 – Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, announces today that it has obtained CE certification for its R-One™ robotic device. As a result, it can begin commercialization in Europe and the Middle East.

R-One™ is the first European robotic solution to obtain the CE mark in the field of interventional cardiology. The robot assists interventional cardiologists in stenting (angioplasty) by enabling precision technologies that…

Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, announces today that the Medical Training and Testing Center (MTC) in Rouen will use its R-One™ robot for future training. Founded in 2017, the MTC is a new center dedicated to training healthcare professionals in a number specialties, with special focus on new technologies.

The R-One™ robot at the MTC will enable the training of future potential users and ensure optimal use by…

100% technical success and no MACE[1] scored in first pre-clinical randomized trial

Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, announces today during the EuroPCR congress that its first robotic solution, R-OneTM, met all its primary efficacy and safety endpoints in the first pre-clinical study.

The prospective, randomized, controlled, multi-operator study evaluated the efficacity and safety of the robotic system compared to a manual procedure. Results showed that…

Rouen, January 30, 2018 – Robocath, a company that conceives and develops cardiovascular robotic systems for the treatment of vascular diseases, announces today the creation of its medical advisory board including global experts and recognized leaders in interventional cardiology.

This committee will help define the clinical strategy of the company and more broadly contribute to the development of future generations of Robocath’s robotic system products.

Philippe Bencteux, president and founder of Robocath, said: “I’m particularly proud and pleased…

Robocath receives an additional €1.25 million financial contribution from Crédit Agricole Innovations et Territoires (CAIT), an innovation fund managed by Supernova Invest. In line with the company’s growth strategy, the new funding aims to increase the resources available to market the R-OneTM product and launch the development of the next generation of robotics dedicated to the treatment of strokes.

Rouen, December 6, 2017 – Robocath, a company that designs and develops innovative robotic solutions for the treatment of vascular diseases (heart attacks,…

Rouen, May 18, 2017 – Robocath, a medical robotics start-up that designs and develops innovative solutions for the treatment of cardiovascular diseases, today announces the conclusion of a new round of fundraising worth €4.7 million ($5.2M). This round was led by M Capital and Normandie Participations. It also involved past investors Go Capital and NCI, who have been supporting the company since 2013. Robocath has already succeeded in raising a total of €1.8 million ($2M) in 2013 and 2015, to…